TARGETED microRNA PROFILING IN GASTRIC CANCER
WITH CLINICAL ASSESSEMENT
Pehlevan Ozel H, Dinç T, Tiryaki RS2, Keşkus AG, Konu O, Kayilioglu SI, Coşkun F
*Corresponding Author: Tolga Dinç, M.D., Associate Professor, Department of General Surgery,
Health Sciences University, Ankara City Hospital, Üniversiteler Mahallesi 1604. Cadde No: 9 Çankaya/
Ankara/Turkey. Tel./Fax: +90-312-552-60-00. Intercom: 121514. Mobile: +90-532-481-22-75. Email:
tolga_dr@hotmail.com
page: 55
download article in pdf format
|
|
Abstract
Although several microRNAs (miRNAs) have been
associated with gastric cancer there is still the need for
identification of stable and validated biomarkers. The
purpose of this study was to determine the alterations of
a specific set of miRNA levels in gastric adenocarcinoma
tissues to identify and validate gastric cancer-specific
miRNAs using paired normal and tumor samples in an
independent patient cohort. Gastric adenocarcinoma and
normal stomach tissue samples of 20 patients who underwent
surgery for gastric cancer were studied. The miRNA
expression profiling was performed for eight miRNAs
in a total of 40 tissue samples using quantitative reverse
transcription polymerase chain reaction (RT-qPCR). Six
out of these eight miRNAs, namely, miR-375-3p, hsamiR-
129-5p, miR-196a-5p, miR-376c-3p, miR-34c-5p
and miR-767-5p, were significantly underexpressed in malignant
tissues of our cohort. Furthermore, the expression
of miR-662 although not significantly different between
normal and tumor tissues, was inversely associated with
age (r = –0.440, p = 0.049). The levels of miR-129-3p and
miR34c-5p were correlated with an increase in the number
of metastatic lymph nodes (r = 0.470, p = 0.036; r = 0.510,
p = 0.020), while and miR-376c-3p levels were negatively
associated with smoking (p = 0.043). In addition, we found
that the variability of miRNA expression in cancerous
tissues was lower than that in normal tissues. Alterations
in miRNA expression in gastric adenocarcinoma tissues
in comparison to healthy tissues of each individual serves
for identification of consistent biomarkers that can be used
for development of diagnostic tools for gastric cancer.
|
|
|
|
 |
Number 27
VOL. 27 (2), 2024 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
